Healthcare News Pharma

Speaker Interview with Dr. Susan Astley for MarketsandMarkets Biomarker and Companion Diagnostics Conference

MarketsandMarkets Biomarker and Companion Diagnostics Conference

London, September 3, 2019 – MarketsandMarkets recently interviewed Dr. Susan Astley, Division of Informatics, Imaging & Data Sciences, University of Manchester regarding MarketsandMarkets Biomarker and Companion Diagnostics Conference taking place on 3rd – 4th October 2019 at Radisson Blu Edwardian, Grafton, London, UK

Q. What are the recent advances in Biomarker research/commercialization and current challenges that need immediate attention?

A. The era of personalised medicine is with us. Biomarkers are crucial to identify those at risk of particular diseases, and those who would benefit from different preventative or therapeutic interventions.

Q. What are the new opportunities emerging in your field of work?

My field is imaging biomarkers of breast cancer. With a wider spectrum of imaging techniques available, we aim to identify the most appropriate screening regime for an individual, based on personal risk and breast composition.

Q. What are the key take away points from your presentation topic which will help in building the knowledge base of attendees?

A. Imaging has a lot to offer in the biomarker field, and with the advent of large databases of images and other data, AI is a key methodology to advance science.

Q. Hope you had a chance to go through the agenda, what are your views on it and how helpful it is to the targeted audience?

A. I am looking forward to hearing from a diverse range of speakers!

Dr. Susan Astley will present on Imaging Biomarkers of breast cancer risk

The latest conference agenda and complete speaker line-up is available to download on the conference page, where you can also register – https://bit.ly/2lLukmp

For more inquiries contact Amit Shelke, Marketing Manager on [email protected]

MarketsandMarkets Conferences

MarketsandMarkets Conferences

About Author

Leave a comment

Your email address will not be published.

You may also like

Pharma Top

CRISPR: An Emerging Technology for Genome Editing

CRISPR is an abbreviation of Clustered Regularly Interspaced Short Palindromic Repeats. In simpler words, it is a family of DNA
Pharma Top

Current Trends in Biomarker Research and Development

It is rightly said ‘Prevention is better than cure’, it is wise to stop something happening or detecting early and that’s